The study aim was to determine treatment persistence rates and to identify causes of discontinuation in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients in clinical practice
Objective: To calculate the persistence, over a period of eight years, the retention rate of first a...
BaCKGroUnd: there is limited information on patients undergoing withdrawal after long-term treatment...
Anti-TNFα blockers have rapidly become a standard treatment for rheumatoid (RA) and psoriatic arthri...
The study aim was to determine treatment persistence rates and to identify causes of discontinuation...
Copyright © 2014 Marta Fabbroni et al.This is an open access article distributed under the Creative ...
Introduction Biologic disease-modifying antirheumatic drugs (bDMARDs) play a pivotal role in the tre...
OBJECTIVE To evaluate treatment persistence in patients with rheumatoid arthritis and ankylosing sp...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be dif...
OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (Ps...
Psoriatic arthritis is a chronic, inflammatory, disabling arthritis affecting up to 30 percent of ps...
This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or o...
Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from sw...
Objective: To calculate the persistence, over a period of eight years, the retention rate of first a...
BaCKGroUnd: there is limited information on patients undergoing withdrawal after long-term treatment...
Anti-TNFα blockers have rapidly become a standard treatment for rheumatoid (RA) and psoriatic arthri...
The study aim was to determine treatment persistence rates and to identify causes of discontinuation...
Copyright © 2014 Marta Fabbroni et al.This is an open access article distributed under the Creative ...
Introduction Biologic disease-modifying antirheumatic drugs (bDMARDs) play a pivotal role in the tre...
OBJECTIVE To evaluate treatment persistence in patients with rheumatoid arthritis and ankylosing sp...
Treatment survival with biological therapy may be influenced by many factors, and it seems to be dif...
OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (Ps...
Psoriatic arthritis is a chronic, inflammatory, disabling arthritis affecting up to 30 percent of ps...
This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or o...
Psoriatic arthritis (PsA) is a chronic condition characterized by a diverse set of symptoms, from sw...
Objective: To calculate the persistence, over a period of eight years, the retention rate of first a...
BaCKGroUnd: there is limited information on patients undergoing withdrawal after long-term treatment...
Anti-TNFα blockers have rapidly become a standard treatment for rheumatoid (RA) and psoriatic arthri...
DOI
Add to ORKG